ライフサイエンスコーパス: myelodysplastic syndrome

1 e induction in normal blood or patients with myelodysplastic syndrome.

2 erformed at our center for acute leukemia or myelodysplastic syndrome.

3 in patients with acute myeloid leukaemia or myelodysplastic syndrome.

4 iated with immunodeficiency, lymphedema, and myelodysplastic syndrome.

5 and patients with secondary AML or high-risk myelodysplastic syndrome.

6 tion remains the only curative treatment for myelodysplastic syndrome.

7 nked to the erythroid lineage in 5q deletion myelodysplastic syndrome.

8 groups according to the diagnosed subtype of myelodysplastic syndrome.

9 ssical DBA and in a 17-year-old patient with myelodysplastic syndrome.

10 lymphoma, myeloproliferative neoplasms, and myelodysplastic syndrome.

11 had acute myelogenous leukemia or high-risk myelodysplastic syndrome.

12 andard treatment for patients with high-risk myelodysplastic syndromes.

13 L), T-cell acute lymphoblastic leukemia, and myelodysplastic syndromes.

14 s, congenital dyserythropoietic anemias, and myelodysplastic syndromes.

15 utations likely contribute to development of myelodysplastic syndromes.

16 crucial to improve outcomes in patients with myelodysplastic syndromes.

17 ith poor survival in patients suffering from myelodysplastic syndromes.

18 precision-medicine concepts in leukemia and myelodysplastic syndromes.

19 fit patients with acute myeloid leukemia or myelodysplastic syndromes.

20 l variables and outcome in 124 patients with myelodysplastic syndromes.

21 gnostic indices in patients with higher-risk myelodysplastic syndromes.

22 30% blasts to focus mainly on patients with myelodysplastic syndromes.

23 itabine) have been approved for treatment of myelodysplastic syndromes.

24 mia and to prolong survival in patients with myelodysplastic syndromes.

25 C in patients with acute myeloid leukemia or myelodysplastic syndromes.

26 ients with intact immune systems, such as in myelodysplastic syndromes.

27 t in patients with anaemia due to lower-risk myelodysplastic syndromes.

28 ral integration site 1 (EVI) and its variant myelodysplastic syndrome 1 (MDS)/EVI encode zinc-finger

29 rative diseases, 18; Hodgkin disease, 2; and myelodysplastic syndrome, 2).

30 One patient developed myelodysplastic syndrome 28 months after receiving radio

31 g tested in phase 2 studies in patients with myelodysplastic syndrome, acute myeloid leukaemia, and m

32 rome, whereas acquired mutations are seen in myelodysplastic syndrome, acute myeloid leukemia, and in

33 in patients with DNMT3A mutations, including myelodysplastic syndrome, acute myeloid leukemia, primar

34 ilty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin l

35 Annualized incidence rate of myelodysplastic syndrome/acute myeloblastic leukemia was

36 orted a 0.27% 8-year cumulative incidence of myelodysplastic syndrome/acute myelogenous leukemia.

37 cterized by lymphedema and predisposition to myelodysplastic syndrome/acute myeloid leukemia (MDS/AML

38 y initiating event, in the transformation to myelodysplastic syndrome/acute myeloid leukemia in patie

39 ve been identified in patients with familial myelodysplastic syndrome/acute myeloid leukemia, monocyt

40 ts were analyzed, including 97 patients with myelodysplastic syndrome and 52 patients with acute myel

41 lly and biologically active in patients with myelodysplastic syndrome and acute myeloid leukaemia.

42 ould be associated with an increased risk of myelodysplastic syndrome and acute myeloid leukemia, col

43 between the disease in these mice and human myelodysplastic syndrome and AML.

44 iation of CSNK1A1 mutations in patients with myelodysplastic syndrome and associated myeloid neoplasm

45 l processes associated with SF3B1 mutations (myelodysplastic syndrome and chronic lymphocytic leukemi

46 Exclusion of hypocellular myelodysplastic syndrome and constitutional BM failure m

47 zacitidine and lenalidomide for patient with myelodysplastic syndrome and have preliminary evidence t

48 familial cases of acute myelogenous leukemia/myelodysplastic syndrome and in MonoMac syndrome.

49 iption factor RUNX1 is frequently mutated in myelodysplastic syndrome and leukemia.

50 ents met present WHO diagnostic criteria for myelodysplastic syndrome and other related myeloid neopl

51 Four patients with associated myelodysplastic syndrome and two who had received haemop

52 tidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, b

53 and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia.

54 of chromosome 7 and 7q [-7/del(7q)] occur in myelodysplastic syndromes and acute myeloid leukemia (AM

55 gnancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia.

56 w-dose cytarabine in patients with high-risk myelodysplastic syndromes and AML are ongoing or planned

57 ations are frequently found in patients with myelodysplastic syndromes and certain leukemias, but how

58 Myelodysplastic syndromes and chronic myelomonocytic leu

59 new therapeutic entries for the treatment of myelodysplastic syndromes and leukaemia.

60 n the pathogenesis of the stem cell disorder myelodysplastic syndromes and myeloid leukaemia.

61 gnancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplas

62 s well-tolerated in patients with lower-risk myelodysplastic syndromes and severe thrombocytopenia an

63 rognostic Scoring System intermediate-1-risk myelodysplastic syndromes and severe thrombocytopenia.

64 in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.

65 e for the treatment of anaemia in lower-risk myelodysplastic syndromes and so could therefore provide

66 tions in genes recurrently mutated in AML or myelodysplastic syndromes and were detectable at very lo

67 with CMML (training cohort, Spanish Group of Myelodysplastic Syndromes) and to validate it in an inde

68 proach against 62 acute myeloid leukemia, 50 myelodysplastic syndrome, and 40 blood DNA samples from

69 ies, including myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

70 treatment-related adverse events (pneumonia, myelodysplastic syndrome, and acute renal failure) and t

71 ed with large granular lymphocytic leukemic, myelodysplastic syndrome, and aplastic anemia.

72 gender, ECOG score, cytogenetic risk group, myelodysplastic syndrome, and hemoglobin, impaired cogni

73 orders of red cell imbalance such as anemia, myelodysplastic syndrome, and polycythemia vera.

74 d leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelate

75 in pathologies, including beta-thalassemia, myelodysplastic syndrome, and viral infection.

76 ncies, such as myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia, r

77 Subtypes of myelodysplastic syndrome are characterized by different

78 Myelodysplastic syndromes are characterised by ineffecti

79 ms of the disease in patients diagnosed with myelodysplastic syndrome, as well as the assessment of t

80 geted screening for CSNK1A1 mutations and 20 myelodysplastic syndrome-associated mutations in 245 add

81 To reveal the functional impact of myelodysplastic syndromes-associated mutations in SRSF2,

82 iting toxicities were noted in patients with myelodysplastic syndrome at 125 mg/m(2) daily x 5, thus

83 leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome between 1999 and 2011 were incl

84 ction of RNA-binding proteins contributes to myelodysplastic syndromes, cancer, and neuropathologies.

85 loid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome cases, suggesting recognition o

86 atment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome) clinical trial (NCT02212561).

87 but increased acute myeloid leukemia and/or myelodysplastic syndrome death rates (RR = 1.62; 95% CI:

88 iple myeloma (MM) and 5q deletion associated myelodysplastic syndrome (del(5q)-MDS), other targets li

89 cute myeloid leukemia and 1 patient with the myelodysplastic syndrome developing into acute myeloid l

90 y: 28 with acute myeloid leukaemia, six with myelodysplastic syndrome, five with chronic myeloid leuk

91 Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommend

92 atment of anaemia associated with lower-risk myelodysplastic syndromes; further studies are ongoing.

93 id leukaemia and six of the 19 patients with myelodysplastic syndrome had a clinical response to trea

94 y acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked b

95 n recipients with acute myeloid leukemia and myelodysplastic syndrome (hazard ratio [HR], 0.09; 95% c

96 d or refractory acute myeloid leukaemia, and myelodysplastic syndromes; here we report the phase 2 re

97 quired aplastic anemia (AA) and hypocellular myelodysplastic syndrome (hMDS) is often difficult, espe

98 s were transient bone-marrow suppression and myelodysplastic syndrome in six patients who had not bee

99 ute myeloid leukaemia and nine patients with myelodysplastic syndrome in the daily x 5 dose-escalatio

100 cute myeloid leukaemia and six patients with myelodysplastic syndrome in the once-weekly dose-escalat

101 ute myeloid leukaemia and four patients with myelodysplastic syndrome in the twice-weekly dose-escala

102 ing use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults.

103 Myelodysplastic syndrome is a rare, chronic hematologica

104 The clinical presentation of myelodysplastic syndromes is highly variable and so accu

105 The standard of care for myelodysplastic syndromes is hypomethylating agents such

106 In del(5q) myelodysplastic syndrome, lenalidomide induces the degra

107 Myelodysplastic syndromes may also present with the morp

108 mia (CML) (n = 646), lymphoma (n = 254), and myelodysplastic syndrome (MDS) (n = 371) who underwent a

109 ed 426 children and adolescents with primary myelodysplastic syndrome (MDS) and 82 cases with seconda

110 atic cohesin mutations have been reported in myelodysplastic syndrome (MDS) and acute myeloid leukemi

111 us deletions of chromosome 7 are frequent in myelodysplastic syndrome (MDS) and acute myeloid leukemi

112 ntinuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemi

113 velopment of some myeloid disorders, such as myelodysplastic syndrome (MDS) and acute myeloid leukemi

114 ergence in their teens or young adulthood of myelodysplastic syndrome (MDS) and acute myeloid leukemi

115 and progenitor cells (HSPCs) from malignant myelodysplastic syndrome (MDS) and AML progenitors.

116 etic mutations drive the pathogenesis of the myelodysplastic syndrome (MDS) and are closely associate

117 to the oncogenic role of miR-22 reported in myelodysplastic syndrome (MDS) and breast cancer, here w

118 ZRSR2 mutations are associated with myelodysplastic syndrome (MDS) and cause U12 splicing de

119 r of the hypoplastic anemia in patients with myelodysplastic syndrome (MDS) and chromosome 5q deletio

120 have frequently been found in patients with myelodysplastic syndrome (MDS) and cytogenetically norma

121 or outcomes in both AML and a mouse model of myelodysplastic syndrome (MDS) and leukemia.

122 as many as 72% of adolescents diagnosed with myelodysplastic syndrome (MDS) and monosomy 7 harbor ger

123 A splicing factors recur among patients with myelodysplastic syndrome (MDS) and related malignancies.

124 n families with multiple cases of late onset myelodysplastic syndrome (MDS) and/or acute myeloid leuk

125 Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers an

126 diagnosis in patients suspected of having a myelodysplastic syndrome (MDS) can be challenging and co

127 plicing machinery are found in almost 50% of myelodysplastic syndrome (MDS) cases.

128 ry anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated

129 bone marrow (BM) samples from patients with myelodysplastic syndrome (MDS) harbor somatic mutations

130 outcome of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has been attributed to fa

131 esis in the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS) has been linked to hetero

132 Myelodysplastic syndrome (MDS) has long been presumed to

133 ory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) have mutations in Splicin

134 Several monogenic causes of familial myelodysplastic syndrome (MDS) have recently been identi

135 nting a set of potential miRNA biomarkers of myelodysplastic syndrome (MDS) in clinical EL samples (m

136 The myelodysplastic syndrome (MDS) is a clonal disorder char

137 The myelodysplastic syndrome (MDS) is a clonal hematologic d

138 Myelodysplastic syndrome (MDS) is clonal disorder charac

139 atients had a concomitant coded diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia

140 associated with predisposition to leukemia, myelodysplastic syndrome (MDS) or dyserythropoietic anem

141 ly, we reported that Asxl1(+/-) mice develop myelodysplastic syndrome (MDS) or MDS and myeloprolifera

142 5q) transfusion-dependent low/intermediate-1 myelodysplastic syndrome (MDS) patients achieve an eryth

143 is of bone marrow-derived stromal cells from myelodysplastic syndrome (MDS) patients and observed wid

144 Only a minority of myelodysplastic syndrome (MDS) patients respond to hypom

145 most common class of genetic alterations in myelodysplastic syndrome (MDS) patients.

146 Approximately one-third of patients with myelodysplastic syndrome (MDS) receiving allogeneic hema

147 Myelodysplastic syndrome (MDS) risk correlates with adva

148 Similarly, high-risk cases of myelodysplastic syndrome (MDS) showed far greater suppre

149 pite the recent evidence of the existence of myelodysplastic syndrome (MDS) stem cells in 5q-MDS pati

150 Myelodysplastic syndrome (MDS) transforms into an acute

151 Adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) typically remain hospital

152 the high response rates of individuals with myelodysplastic syndrome (MDS) with deletion of chromoso

153 lidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromoso

154 allogeneic transplantation in patients with myelodysplastic syndrome (MDS) within a randomized trial

155 Myelodysplastic syndrome (MDS), a hematopoietic stem cel

156 PHD was defined as diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (

157 ently in patients with clonal hematopoiesis, myelodysplastic syndrome (MDS), and acute myeloid leukem

158 C2), are observed in ~\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute my

159 Many underlying diseases, like myelodysplastic syndrome (MDS), develop preferentially i

160 for up to 42 days and developed features of myelodysplastic syndrome (MDS), including dysplastic neu

161 In a subset of patients with non-del(5q) myelodysplastic syndrome (MDS), lenalidomide promotes er

162 ring as a myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or mixed MDS/MPN overlap

163 ons of TET2 are frequently observed in human myelodysplastic syndrome (MDS), which is a clonal malign

164 of Asxl2 in mice leads to the development of myelodysplastic syndrome (MDS)-like disease.

165 roleukemia, and when BM blasts are < 20%, as myelodysplastic syndrome (MDS).

166 wnregulation was associated with a subset of myelodysplastic syndrome (MDS).

167 ated on the X chromosome-are associated with myelodysplastic syndrome (MDS).

168 with a 20% risk of evolving into leukemia or myelodysplastic syndrome (MDS).

169 ted in the common deleted region for del(5q) myelodysplastic syndrome (MDS).

170 ctor U2AF35 are found in several cancers and myelodysplastic syndrome (MDS).

171 leukemia, BCR-ABL1 negative (aCML) is a rare myelodysplastic syndrome (MDS)/myeloproliferative neopla

172 juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neopla

173 hronic myeloid leukemia (CML, n = 1079); and myelodysplastic syndrome (MDS, n = 1197).

174 The prognosis of myelodysplastic syndromes (MDS) after allogeneic stem ce

175 ening complication in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukae

176 ve indicator of disease progression for both myelodysplastic syndromes (MDS) and acute myeloid leukae

177 SALL4 is aberrantly expressed in human myelodysplastic syndromes (MDS) and acute myeloid leukem

178 l genes) are commonly found in patients with myelodysplastic syndromes (MDS) and acute myeloid leukem

179 Myelodysplastic syndromes (MDS) and acute myeloid leukem

180 opoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocyt

181 progenitor cells (HSPCs) from patients with Myelodysplastic syndromes (MDS) and healthy donors.

182 of malignant clones in the hematopoiesis of myelodysplastic syndromes (MDS) and its impact on respon

183 entiation, as well as in the pathogenesis of myelodysplastic syndromes (MDS) and leukemia.

184 iew the current understanding of genomics in myelodysplastic syndromes (MDS) and leukemias and the li

185 Our knowledge of the genetic basis of myelodysplastic syndromes (MDS) and myelodysplastic/myel

186 Myelodysplastic syndromes (MDS) and myeloproliferative n

187 A common deleted region (CDR) in both myelodysplastic syndromes (MDS) and myeloproliferative n

188 ost common structural abnormality in primary myelodysplastic syndromes (MDS) and therapy-related myel

189 Myelodysplastic syndromes (MDS) are a diverse group of b

190 Myelodysplastic syndromes (MDS) are a group of neoplasms

191 Myelodysplastic syndromes (MDS) are a heterogeneous grou

192 Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with dise

193 Myelodysplastic syndromes (MDS) are characterized by ine

194 Myelodysplastic syndromes (MDS) are clonal disorders of

195 Myelodysplastic syndromes (MDS) are clonal hematopoietic

196 Myelodysplastic syndromes (MDS) are common hematologic d

197 Although myelodysplastic syndromes (MDS) are defined by cytopenia

198 Higher-risk myelodysplastic syndromes (MDS) are defined by patients

199 Myelodysplastic syndromes (MDS) are driven by complex ge

200 Once thought to be rare disorders, the myelodysplastic syndromes (MDS) are now recognized as am

201 Myelodysplastic syndromes (MDS) are stem cell disorders

202 emic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythro

203 atients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear.

204 Myelodysplastic syndromes (MDS) are uncommon in children

205 myelodysplasia as they aged, culminating in myelodysplastic syndromes (MDS) at 24 months of age, wit

206 mprove survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studie

207 including chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS) either sensitive or resi

208 g chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) in human.

209 nt treatment capable of curing patients with myelodysplastic syndromes (MDS) is allogeneic haematopoi

210 adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is challenging because o

211 The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and va

212 The diagnosis of patients with myelodysplastic syndromes (MDS) is largely dependent on

213 eased autoantibody reactivity in plasma from Myelodysplastic Syndromes (MDS) patients may provide nov

214 The diagnosis of myelodysplastic syndromes (MDS) remains problematic due

215 e factor (SF) genes occur more frequently in myelodysplastic syndromes (MDS) than in acute myeloid le

216 ncluding myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MPN/MDS, have ident

217 e the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS p

218 T) for older patients (age >/=60 years) with myelodysplastic syndromes (MDS), focusing on how to choo

219 otypes resembling those found in early-stage myelodysplastic syndromes (MDS), including ineffective e

220 subclasses of patients with acute leukemias, myelodysplastic syndromes (MDS), myeloproliferative neop

221 occur in approximately 11% of patients with myelodysplastic syndromes (MDS), the most common adult m

222 In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existe

223 elucidate differential roles of mutations in myelodysplastic syndromes (MDS), we investigated clonal

224 premalignant hematologic conditions, such as myelodysplastic syndromes (MDS).

225 is the predominant clinical manifestation of myelodysplastic syndromes (MDS).

226 a somatic cytogenetic abnormality present in myelodysplastic syndromes (MDS).

227 ogenesis of age-related disorders, including myelodysplastic syndromes (MDS).

228 effective erythropoiesis in a mouse model of myelodysplastic syndromes (MDS).

229 ctable in approximately 50% of patients with myelodysplastic syndromes (MDS).

230 standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS).

231 al killer (NK) lymphoid deficiency; familial myelodysplastic syndromes (MDS)/acute myeloid leukemia (

232 Familial clustering of myelodysplastic syndromes (MDSs) and acute myeloid leuke

233 he U2 snRNP component SF3B1 are prominent in myelodysplastic syndromes (MDSs) and other cancers and h

234 Myelodysplastic syndromes (MDSs) are a group of hematopo

235 Myelodysplastic syndromes (MDSs) are a group of heteroge

236 Lower-risk myelodysplastic syndromes (MDSs) are defined as having l

237 Myelodysplastic syndromes (MDSs) are hematopoietic stem

238 The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on b

239 Recent studies have demonstrated that myelodysplastic syndromes (MDSs) arise from a small popu

240 Myelodysplasia is a diagnostic feature of myelodysplastic syndromes (MDSs) but is also found in ot

241 mDia1, a chromosome 5q gene, contributes to myelodysplastic syndromes (MDSs) by increasing innate im

242 frequent class of mutations in patients with myelodysplastic syndromes (MDSs) in particular.

243 The myelodysplastic syndromes (MDSs) include a spectrum of s

244 Despite genetic heterogeneity, myelodysplastic syndromes (MDSs) share features of cytol

245 with myeloid malignancies, most commonly in myelodysplastic syndromes (MDSs), and are associated wit

246 marrow microenvironment (BMME) is altered in myelodysplastic syndromes (MDSs).

247 One patient received a diagnosis of myelodysplastic syndrome more than 51 weeks after radioi

248 excess risk of acute myeloid leukemia and/or myelodysplastic syndrome mortality in radiologists who g

249 owever, 2 patients with -7 and 7q- developed myelodysplastic syndrome, most likely due to haploinsuff

250 1206 adults with untreated AML or high-risk myelodysplastic syndrome, mostly younger than 60 years o

251 lasms (MPN), these patients can present with myelodysplastic syndrome/MPN, as well as de novo or seco

252 heterodimer was unaffected by cancer-linked myelodysplastic syndrome mutants.

253 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/ myeloproliferative neoplasm wh

254 s, and diagnoses were acute leukemias (51%), myelodysplastic syndrome/myeloproliferative neoplasm (19

255 JMML is categorized as an overlap myelodysplastic syndrome/myeloproliferative neoplasm (MD

256 d for acute myeloid leukemia (AML, n = 138), myelodysplastic syndrome (n = 28), or acute lymphoblasti

257 In this clinical trial, patients with myelodysplastic syndrome (n=25) received reduced decitab

258 the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%)

259 (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=

260 al Working Group (IWG) response criteria for myelodysplastic syndromes nor the IWG Myeloproliferative

261 py; the control group included patients with myelodysplastic syndromes not targeted by this warning.

262 ult patients with acute myeloid leukemia and myelodysplastic syndrome on induction therapy or allogen

263 rom nine North American medical centres with myelodysplastic syndrome or acute myeloid leukaemia that

264 Patients with myelodysplastic syndrome or acute myeloid leukaemia who

265 ble safety profile in patients with advanced myelodysplastic syndrome or acute myeloid leukaemia.

266 In 38% of patients with myelodysplastic syndromes or acute myeloid leukaemia, in

267 ng System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic m

268 ications such as severe bone marrow failure, myelodysplastic syndrome, or acute myeloid leukemia.

269 ome, secondary acute myeloid leukaemia after myelodysplastic syndrome, or de-novo acute myeloid leuka

270 leukaemia, chronic myelomonocytic leukaemia, myelodysplastic syndrome, or myelofibrosis who were refr

271 9) for patients with acute myeloid leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma, the t

272 transplantation is curative in up to 40% of myelodysplastic syndrome patients.

273 G in patients with acute myeloid leukemia or myelodysplastic syndrome receiving myeloablative conditi

274 We detected coexisting myelodysplastic syndrome-related gene mutations in patie

275 yelodysplastic CMML is largely inspired from myelodysplastic syndromes, relying on erythropoiesis-sti

276 mbocytopenia in adult patients with advanced myelodysplastic syndrome, secondary acute myeloid leukae

277 In patients with newly diagnosed higher-risk myelodysplastic syndromes, self-reported fatigue severit

278 In myelodysplastic syndromes, SF3B1 mutations appear to be

279 yeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized com

280 Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/MDS) represent severe l

281 with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes, that is, idarubicine-cytarabi

282 improves survival in patients with high-risk myelodysplastic syndrome, the overall response remains a

283 In myelodysplastic syndromes, thrombocytopenia is associate

284 .6%) with marrow failure and 11 (24.4%) with myelodysplastic syndrome underwent HCT using matched unr

285 the maximum tolerated dose in patients with myelodysplastic syndrome was 90 mg/m(2) daily x 5.

286 in patients with acute myeloid leukaemia and myelodysplastic syndrome was initially established at 50

287 mia and thrombocytopenia, and a diagnosis of myelodysplastic syndrome was made.

288 Adults (>/=18 years) with myelodysplastic syndromes were consecutively enrolled wi

289 21, 2013, and Feb 12, 2015, 58 patients with myelodysplastic syndromes were enrolled in the 12 week b

290 Myelodysplastic syndromes were not rare (2.3%).

291 secutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablat

292 18 to 65 years of age with acute leukemia or myelodysplastic syndrome who underwent myeloablative HLA

293 ents with non-APL acute myeloid leukemia and myelodysplastic syndrome who were treated on a previousl

294 rug in phase 3 clinical trials for high-risk myelodysplastic syndrome whose molecular target had rema

295 participants were previously untreated with myelodysplastic syndrome with an International Prognosti

296 sed or refractory acute myeloid leukaemia or myelodysplastic syndrome with bone marrow blasts more th

297 ene SF3B1 are found in >80% of patients with myelodysplastic syndrome with ring sideroblasts (MDS-RS)

298 g best supportive care only in patients with myelodysplastic syndromes with excess blasts after failu

299 median survival, 328 days) characteristic of myelodysplastic syndromes with symptoms including anemia

300 dine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloprolif